(Q27015772)

English

Pharmacokinetics, efficacy and safety profiles of etanercept monotherapy in Japanese patients with rheumatoid arthritis: review of seven clinical trials

scientific article

In more languages

Statements

scholarly article

1 reference

9 references

13 March 2019

17 June 2019

30 June 2019

31 July 2019

20 November 2019

27 November 2019

13 December 2019

15 December 2019

14 November 2020

Pharmacokinetics, efficacy and safety profiles of etanercept monotherapy in Japanese patients with rheumatoid arthritis: review of seven clinical trials (English)

0 references

rheumatoid arthritis

9 references

13 March 2019

17 June 2019

30 June 2019

31 July 2019

20 November 2019

27 November 2019

13 December 2019

15 December 2019

14 November 2020

cell surface receptor

1 reference

31 July 2019

1 reference

20 November 2019

1 reference

27 November 2019

1 reference

13 December 2019

membrane protein

1 reference

15 December 2019

pharmacokinetics

1 reference

based on heuristic

inferred from title

disease-modifying antirheumatic drug

1 reference

14 November 2020

Tsutomu Takeuchi

1

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24842477%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

author name string

Nobuyuki Miyasaka

2

2 references

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24842477%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

Shinichi Kawai

3

2 references

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24842477%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

Naonobu Sugiyama

4

2 references

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24842477%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

Hirotoshi Yuasa

5

2 references

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24842477%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

Noriaki Yamashita

6

2 references

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24842477%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

Noriko Sugiyama

7

2 references

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24842477%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

Lorin Craig Wagerle

8

2 references

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24842477%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

Bonnie Vlahos

9

2 references

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24842477%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

Joseph Wajdula

10

2 references

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24842477%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

language of work or name

1 reference

publication date

March 2015

1 reference

1 March 2015

9 references

13 March 2019

17 June 2019

30 June 2019

31 July 2019

20 November 2019

27 November 2019

13 December 2019

15 December 2019

14 November 2020

Modern Rheumatology

11 references

13 March 2019

17 June 2019

30 June 2019

31 July 2019

20 November 2019

27 November 2019

13 December 2019

15 December 2019

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24842477%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

14 November 2020

25

2 references

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24842477%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

2

2 references

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24842477%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

173-186

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24842477%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

Estimates of the prevalence of and current treatment practices for rheumatoid arthritis in Japan using reimbursement data from health insurance societies and the IORRA cohort (I).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4445012

28 September 2017

Association between anti-TNF-α therapy and interstitial lung disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4445012

28 September 2017

Pneumocystis jirovecii infection: an emerging threat to patients with rheumatoid arthritis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4445012

28 September 2017

Golimumab monotherapy in Japanese patients with active rheumatoid arthritis despite prior treatment with disease-modifying antirheumatic drugs: results of the phase 2/3, multicentre, randomised, double-blind, placebo-controlled GO-MONO study through

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4445012

28 September 2017

Golimumab in combination with methotrexate in Japanese patients with active rheumatoid arthritis: results of the GO-FORTH study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4445012

28 September 2017

Effectiveness and safety of adalimumab in Japanese patients with rheumatoid arthritis: retrospective analyses of data collected during the first year of adalimumab treatment in routine clinical practice (HARMONY study).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4445012

28 September 2017

Safety and effectiveness of switching from infliximab to etanercept in patients with rheumatoid arthritis: results from a large Japanese postmarketing surveillance study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4445012

28 September 2017

Safety and effectiveness responses to etanercept for rheumatoid arthritis in Japan: a sub-analysis of a post-marketing surveillance study focusing on the duration of rheumatoid arthritis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4445012

28 September 2017

Postmarketing surveillance of safety and effectiveness of etanercept in Japanese patients with rheumatoid arthritis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4445012

28 September 2017

The Japanese experience with biologic therapies for rheumatoid arthritis.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4445012

28 September 2017

Postmarketing surveillance of the safety and effectiveness of etanercept in Japan

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4445012

28 September 2017

Clinical investigation in highly disease-affected rheumatoid arthritis patients in Japan with adalimumab applying standard and general evaluation: the CHANGE study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4445012

28 September 2017

Update on the Japanese guidelines for the use of infliximab and etanercept in rheumatoid arthritis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4445012

28 September 2017

Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumab

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4445012

28 September 2017

What should be our treatment goal in rheumatoid arthritis today?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4445012

28 September 2017

Guidelines for the proper use of etanercept in Japan

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4445012

28 September 2017

Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4445012

28 September 2017

Burden of major musculoskeletal conditions.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4445012

28 September 2017

The Stanford Health Assessment Questionnaire: a review of its history, issues, progress, and documentation.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4445012

28 September 2017

Phase II dose-response study of abatacept in Japanese patients with active rheumatoid arthritis with an inadequate response to methotrexate.

2 references

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4445012

31 May 2018

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4445012

28 November 2018

A phase 3 randomized, double-blind, multicenter comparative study evaluating the effect of etanercept versus methotrexate on radiographic outcomes, disease activity, and safety in Japanese subjects with active rheumatoid arthritis

2 references

https://api.crossref.org/works/10.3109%2F14397595.2014.914014

21 January 2018

https://pubmed.ncbi.nlm.nih.gov/24842477

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Incidence and risk factors for serious infection in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors: a report from the Registry of Japanese Rheumatoid Arthritis Patients for Longterm Safety

1 reference

https://api.crossref.org/works/10.3109%2F14397595.2014.914014

21 January 2018

Clinical and radiological features of acute-onset diffuse interstitial lung diseases in patients with rheumatoid arthritis receiving treatment with biological agents: importance of Pneumocystis pneumonia in Japan revealed by a multicenter study.

1 reference

https://api.crossref.org/works/10.3109%2F14397595.2014.914014

21 January 2018

A retrospective study of serum KL-6 levels during treatment with biological disease-modifying antirheumatic drugs in rheumatoid arthritis patients: a report from the Ad Hoc Committee for Safety of Biological DMARDs of the Japan College of Rheumatolo

1 reference

https://api.crossref.org/works/10.3109%2F14397595.2014.914014

21 January 2018

Safety and effectiveness of 6 months' etanercept monotherapy and combination therapy in Japanese patients with rheumatoid arthritis: effect of concomitant disease-modifying antirheumatic drugs

1 reference

https://api.crossref.org/works/10.3109%2F14397595.2014.914014

21 January 2018

Continuation of Methotrexate Resulted in Better Clinical and Radiographic Outcomes Than Discontinuation upon Starting Etanercept in Patients with Rheumatoid Arthritis: 52-week Results from the JESMR Study

1 reference

https://api.crossref.org/works/10.3109%2F14397595.2014.914014

21 January 2018

Postmarketing surveillance of the safety profile of infliximab in 5000 Japanese patients with rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.3109%2F14397595.2014.914014

21 January 2018

Safety and effectiveness of adalimumab in Japanese rheumatoid arthritis patients: postmarketing surveillance report of the first 3,000 patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4445012

28 November 2018

Clinical trial safety and mortality analyses in patients receiving etanercept across approved indications.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4445012

28 November 2018

Update on the Japanese guidelines for the use of infliximab and etanercept in rheumatoid arthritis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4445012

28 November 2018

The Health Assessment Questionnaire (HAQ).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4445012

28 November 2018

A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis

1 reference

https://pubmed.ncbi.nlm.nih.gov/24842477

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Etanercept versus methotrexate in patients with early rheumatoid arthritis: two-year radiographic and clinical outcomes

1 reference

https://pubmed.ncbi.nlm.nih.gov/24842477

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/24842477

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The comparability of etanercept pharmacokinetics in healthy Japanese and American subjects

1 reference

https://pubmed.ncbi.nlm.nih.gov/24842477

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Drug retention rates and relevant risk factors for drug discontinuation due to adverse events in rheumatoid arthritis patients receiving anticytokine therapy with different target molecules

1 reference

https://pubmed.ncbi.nlm.nih.gov/24842477

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Time-dependent increased risk for serious infection from continuous use of tumor necrosis factor antagonists over three years in patients with rheumatoid arthritis

1 reference

https://pubmed.ncbi.nlm.nih.gov/24842477

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.3109/14397595.2014.914014

2 references

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24842477%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

release_ftzi44v7pnfq3l2hqya2y3sezu

0 references

PMC publication ID

2 references

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24842477%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

PubMed publication ID

2 references

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24842477%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q27015772&oldid=1946855128"